Biobanks Industry: Market Size & Forecast 2026

Biobanking encompasses the equipment, consumables, software, and services used to preserve biological specimens at controlled temperatures and link them to health and genomic data. The market was valued at approximately $7.81 billion in 2025 and is projected to expand at a compound annual growth rate of about 9.1% through the end of the decade. This growth reflects biobanks' transition from niche research assets to foundational infrastructure for modern life sciences.

• •Demand is shifting from small academic collections to large, networked, and commercial biobanks.
• •Sample types span blood, tissue, nucleic acids, stem cells, and organoids used across research and clinical applications.
• •Standardized quality, consent, and data-governance frameworks are increasingly central to market participation.

The strongest growth driver is the rapid expansion of genomics, biomarker discovery, and personalized medicine, all of which depend on large, well-characterized sample collections with linked clinical data. Aging populations and the rising burden of chronic and complex diseases are increasing the need for longitudinal biospecimen resources. At the same time, public health agencies and private funders are investing in population-scale cohorts, biorepositories, and biobank networks.

• •Precision medicine and large-scale genomics programs require millions of high-quality, annotated samples.
• •Growth in cell and gene therapy development is driving demand for storage of cells, tissues, and engineered biomaterials.
• •Public-private partnerships and government-funded cohort studies are expanding national and regional biobank capacity.

The market is typically segmented by product and service type (equipment, consumables, software, and services), by sample type (blood, cells and tissue, nucleic acids, and others), and by end user (academic and research institutes, hospitals, and pharmaceutical and biotechnology companies). Geographically, North America holds the largest share, supported by mature research funding, established biorepositories, and strong pharmaceutical activity, while Europe benefits from harmonized biobanking networks and a large academic base. The Asia-Pacific region is the fastest-growing market, led by investments in China, Japan, South Korea, and India.

• •Pharmaceutical and biotechnology companies represent a growing share of demand as they outsource sample handling and storage.
• •Cryogenic storage systems, including ultra-low freezers and automated sample management, account for a significant equipment segment.
• •Population-scale projects such as Genomics England and national programs in China are reshaping regional leadership.

What are the recent trends and outlook?

Automation and digitalization are reshaping biobank operations, with laboratory robotics, IoT-enabled temperature monitoring, and laboratory information management systems replacing manual workflows. Virtual and federated biobank models are emerging, allowing researchers to query sample metadata and request access without physically moving specimens. Looking ahead, the industry is expected to deepen its integration with artificial intelligence, multi-omics research, and regulatory-grade data standards, supporting continued double-digit growth through the late 2020s.

• •AI-driven sample matching and data analytics are accelerating the use of biobanks in drug discovery.
• •Cloud-based LIMS and federated data platforms are enabling cross-institutional collaboration while protecting donor privacy.
• •Regulatory harmonization around consent, sample provenance, and data sharing is becoming a competitive differentiator.